HER2-positive Metastatic Breast Cancer in Kazakhstan

Starting soon

Conditions studied: Metastatic Breast Cancer

In brief

Planned study population consists of approximately 240 adult patients with HER2-positive mBC receiving anti-HER2 therapy in 12 oncological centers (in each center it is expected to recruit about 20 patients) in different regions in order to provide representative study sample. Patients will be included consecutively from the least recent diagnosis (within defined time period). Planned retrospective follow-up period for 1 patient is a period starting from the date of mBC diagnosis until end study or until patient's death, whichever occurs first. End of study will be at least 12 months after the latest date of mBC diagnosis to ensure all patients have the opportunity to contribute at least 12 months of data.

Key facts

Study ID

NCT07593196

Run by

AstraZeneca

People needed

240

Starts

2026-05-19

Expected to finish

2027-01-30

Last updated by the study team

2026-05-18

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with HER2-positive mBC who are receiving or have started any anti-HER2 therapy (except for trastuzumab deruxtecan) at the time of inclusion
• The diagnosis of mBC was established between the 1st January 2022 to 31st December 2023
• Patients with the availability of at least 24 months of follow-up data (from the date of mBC diagnosis) in the medical records at the participating site, unless patient died/moved or refused the therapy within the first 24 months of diagnosis
• Age ≥18 years at the time of inclusion

You may not qualify if…

• Presence of other malignancies within the period from mBC diagnosis until the timepoint of data collection
• Patients received trastuzumab deruxtecan
• The participation in any interventional trial within period since diagnosis until the end of study

Where it is running

• 'Regional Cancer Centre' Uralsk — Oral, Kazakhstan, Kazakhstan
• Medical Centre of the Marat Ospanov West Kazakhstan Medical University, Aktobe — Aktobe, Kazakhstan
• 'Kazakh Research Institute of Oncology and Radiology (KAZNIOR)' — Almaty, Kazakhstan
• Almaty Cancer Centre — Almaty, Kazakhstan
• 'Multidisciplinary Medical Centre' of the Astana City Administration — Astana, Kazakhstan
• National Cancer Research Centre, Astana — Astana, Kazakhstan
• 'Karaganda General Hospital No. 3' of the Karaganda Region Health Department — Karaganda, Kazakhstan
• 'General Regional Hospital' of the municipal state institution 'Health Department of the Akimat of North Kazakhstan Region' Petropavlovsk — Petropavl, Kazakhstan
• 'Centre for Nuclear Medicine and Oncology' Abai Regional Health Authority Semey — Semey, Kazakhstan
• 'Shymkent City General Hospital with Oncology Centre' under the Shymkent City Health Department — Shymkent, Kazakhstan
• 'Regional Clinical Hospital' of the Health Department of the Turkestan Region — Shymkent, Kazakhstan
• 'The Zhambyl Regional Multidisciplinary Centre for Oncology and Surgery' of the Health Department of the Zhambyl Regional Administration, Taraz — Taraz, Kazakhstan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.